PANCREATIC ADENOCARCINOMA ADVANCED OR METASTATIC

Clinical trials for PANCREATIC ADENOCARCINOMA ADVANCED OR METASTATIC explained in plain language.

Never miss a new study

Get alerted when new PANCREATIC ADENOCARCINOMA ADVANCED OR METASTATIC trials appear

Sign up with your email to follow new studies for PANCREATIC ADENOCARCINOMA ADVANCED OR METASTATIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1

New drug CT-95 targets tough cancers in early trial

Disease control Recruiting now

This early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…

Matched conditions: PANCREATIC ADENOCARCINOMA ADVANCED OR METASTATIC

Phase: PHASE1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control

Last updated Jun 15, 2026 19:03 UTC

PANCREATIC ADENOCARCINOMA ADVANCED OR METASTATIC

Get alerted when new PANCREATIC ADENOCARCINOMA ADVANCED OR METASTATIC trials appear

New drug CT-95 targets tough cancers in early trial